BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting - - IND clearance expands Company's advanced clinical pipeline for ...

BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting –– IND ...

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative ...

The novel drug CT-179 ... How Healthy Stem Cells Turn Into Oral Cancer Feb. 4, 2025 — Researchers have identified the molecular and cellular mechanisms that transform healthy stem cells into ...

BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) (NASDAQ: BRTX), a clinical stage regenerative ...

Mini-Stem System® received its CE Mark approval in 2024 Dr. Neophytos Demetriades, Dr. Marco Spoliti, and Dr. Francesco Calvani ...

Stem cell biotechnology is a field of biotechnology ... Here, the authors present an approach for the production of muscle and adipose cell-laden microtissues using edible porous microcarriers ...

BioRestorative Therapies (NASDAQ:BRTX – Get Free Report) and Quipt Home Medical (NASDAQ:QIPT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will ...

The global Orthobiologics Market is valued at $6.56 billion in 2024 and is projected to reach a value of $10.4 billion by ...

Stem cell therapy is emerging as a potential treatment for different conditions in endocrinology, including diabetes and Addison disease.

Novadip Biosciences’s bone grafting material NVDX3 has seen all patients achieve bone fracture union in a 12-month Phase ...

Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions –– Reflects positive preliminary Phase 2 Safety ...